Site Editor

David S. Ettinger, MD, FACP, FCCP


WCLC 2022: Interim Analysis of Overall Survival With Atezolizumab in Resected NSCLC From IMpower010

By: Vanessa A. Carter, BS
Posted: Tuesday, August 16, 2022

Conducted by Caicun Zhou, MD, PhD, of Shanghai Pulmonary Hospital, China, and colleagues, the phase III IMpower010 trial was the first immunotherapy study to demonstrate a significant improvement in disease-free survival with adjuvant atezolizumab versus best supportive care in resected non–small cell lung cancer (NSCLC). During the International Association for the Study of Lung Cancer (IASLC) 2022 World Conference on Lung Cancer (Abstract PL03.09), Enriqueta Felip, MD, PhD, of Vall d’Hebron University Hospital, Barcelona, presented the interim analysis of overall survival after 13 months of follow-up.

“At the first overall survival interim analysis, an overall survival trend in favor of atezolizumab was observed in the PD-L1 tumor cell ≥ 1% stage II to IIIA population, but not in the all-randomized stage II to IIIA or intent-to-treat populations,” stated the investigators. “No new safety signals were observed with additional follow-up. IMpower010 will continue to the final disease-free survival analysis, with further overall survival results.”

This trial enrolled 1,005 patients with completely resected stage IB to IIIA NSCLC determined to have an Eastern Cooperative Oncology Group performance score of 0 to 1. Participants were administered up to four 21-day cycles of doublet chemotherapy and then were randomly assigned to receive 16 cycles of atezolizumab (n = 507) or best supportive care (n = 498).

With a median follow-up of 45 months, 25% of patients had died by the clinical cutoff date. Adverse events of grade 3 or 4 affected nearly twice as many patients in the atezolizumab arm (22.0%) as those receiving best supportive care (11.5%); 18.2% of patients discontinued treatment because of these events. Additionally, 52.1% of individuals who received immunotherapy experienced adverse events of special interest. Grade 5 adverse events were reported in 0.8% of patients treated with atezolizumab, but none occurred after the clinical cutoff date.

Disclosure: For disclosures of the study authors, visit

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.